Active Motif, the industry leader in developing and delivering tools to enable epigenetics and gene regulation research, and BenchSci, a life science machine learning startup backed by Google’s AI fund, have announced a new partnership to provide researchers with high-quality epigenetics-related research products for accelerating scientific discoveries.

Antibody products help researchers in their scientific inquiry to decode the function, regulation, and interactions of the genes, their encoded proteins, and the epigenetic mechanisms. However, low-quality antibodies have been a major contributing factor towards research irreproducibility. Poorly validated antibodies have resulted in substantial amounts of wasted money, time, and effort, not to mention inconclusive scientific results. This affects the pace of scientific discovery, slows productivity, and delays the development of novel therapies.

To circumvent this problem, researchers dedicate a lot of time to review scientific literature, identify relevant published data, and compare them to decide which antibodies are most likely to work in their experiments. However, more than 38 million scientific papers have been published since 1980, a number that doubles every nine years. Therefore, this manual process can be quite tedious, requiring hours and sometimes days, to find useful data—if it can be found at all.

Active Motif’s partnership with BenchSci aims to solve this problem by coupling the company’s extensive catalog of validated products with BenchSci’s industry-leading artificial intelligence platform. Using machine learning, BenchSci will identify published data for Active Motif’s products in open- and closed-access datasets, display published and vendor-provided validation figures, and allow researchers to search using important experimental variables.

Gary Shiels, Vice President of Marketing at Active Motif, believes that the relationship with BenchSci will increase the discoverability of specialist antibody suppliers such as Active Motif to offer highly validated antibody products and provide complete and innovative custom solutions to scientists. “We are excited to join forces with BenchSci to accelerate epigenetics and gene regulation research,” says Shiels.

“Active Motif’s dedication to advancing epigenetics research with high-quality, reliable reagents mirrors our mission to accelerate biomedical research with machine learning,” says Liran Belenzon, CEO, BenchSci. “We are excited to partner with Active Motif and increase discoverability of its epigenetics-related products in more than 2,000 academic institutions and 15 top pharmaceutical companies worldwide.”

ABOUT ACTIVE MOTIF

Active Motif is the industry leader in developing and delivering innovative tools to enable and accelerate epigenetics and gene regulation research. We are committed to providing the highest quality products and superior service to serve the life science, clinical and pharmaceutical/drug discovery communities. Our antibodies are manufactured in-house, where they undergo rigorous developmental and validating procedures to ensure their quality and performance in applications you care about, such as chromatin immunoprecipitation (ChIP), ChIP-Seq, Western blotting, and immunofluorescence. Whether you are an expert in the field of epigenetics or a researcher interested in integrating epigenetics research into your studies, Active Motif offers a comprehensive portfolio of epigenetics-related products and services and the support of our team of epigenetic experts to provide complete and innovative solutions to tackle your scientific inquiries. To learn more about Active Motif and our wide range of products and custom services, please visit https://www.activemotif.com.

ABOUT BENCHSCI

Backed by Google’s AI fund, Gradient Ventures, and built by life scientists for life scientists, BenchSci’s AI reads biomedical papers and maps their findings to navigate researchers to new discoveries faster. Using data from more than 10 million publications, this map leverages the world’s most comprehensive, evidence-based biological knowledge graph. Unlike other bioinformatics tools, it helps researchers find unexpected connections, generate unconsidered hypotheses, avoid repeating prior experiments, and adopt the best materials and methods. This catalyzes faster, more cost-effective, and higher impact discoveries by our academic and industry partners. BenchSci’s first product, an antibody search engine, helps researchers find reliable antibodies up to 24x faster and use commercial antibodies up to 75% more cost-effectively. It now powers discoveries in 15 of the top 20 pharmaceutical companies and more than 2,000 academic institutions.